In this week's video, Dr. Brian G.M. Durie explains how bispecific antibodies work and why they are being studied in clinical trials  to treat myeloma.

Bispecific antibodies are showing great promise in clinical trials.

Have a question? Submit it to

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at

Previous Post
New Guidelines for Superior Imaging, a Possible Cause of Post-Transplant Relapse, and the Future of Genetic Therapy: Myeloma News in Brief
Next Post
Second Asian Myeloma Network Summit in Beijing, China Is a Big Success

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.